Napa Therapeutics Ltd. has identified ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of inflammatory disorders, metabolic diseases, cancer, obesity, diabetes, rheumatoid arthritis, fibrosis and neurodegeneration, among others.